Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

Inclusion Criteria: Patients must meet all of the following conditions to be eligible for the study: * Age 18-75 years. * Patients with persistent AF scheduled for first-time catheter ablation. * Diagnosed with OSA. * Able to tolerate CPAP therapy. * Capable of understanding and complying with the study protocol. * Willing to sign the informed consent form. Exclusion Criteria: Patients meeting any of the following criteria will be excluded from the study: * Secondary AF. * Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view). * Left ventricular ejection fraction \< 30%. * Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic). * Pregnant or breastfeeding women. * History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening. * History of stroke or transient ischemic attack within 6 months prior to screening. * Perioperative complications related to the ablation procedure occurring prior to randomization. * Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons. * Life expectancy \< 1 year. * Central sleep apnea. * Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \> 30kg/m² and awake PaCO₂ \> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \> 1 episode of respiratory failure or hypercapnia. * Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization. * Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery. * Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year. * Current participation in other drug or device trials.